International Clinical Trial: Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819799) titled 'Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis' on Sept. 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Attovia Therapeutics Inc

Condition: Ulcerative Colitis (UC)

Intervention: Drug: ATTO-1091

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: December 14, 2026

Target Sample Size: 96

To know more, visit https://clinicaltrials.gov/...